1. Home
  2. HOPE vs URGN Comparison

HOPE vs URGN Comparison

Compare HOPE & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hope Bancorp Inc.

HOPE

Hope Bancorp Inc.

HOLD

Current Price

$13.54

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$37.31

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOPE
URGN
Founded
1986
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.4B
IPO Year
2000
2016

Fundamental Metrics

Financial Performance
Metric
HOPE
URGN
Price
$13.54
$37.31
Analyst Decision
Buy
Strong Buy
Analyst Count
2
7
Target Price
$14.50
$29.29
AVG Volume (30 Days)
1.2M
649.5K
Earning Date
04-28-2026
05-06-2026
Dividend Yield
4.53%
N/A
EPS Growth
N/A
N/A
EPS
0.23
N/A
Revenue
N/A
$1,128,000.00
Revenue This Year
$42.00
$129.09
Revenue Next Year
$19.66
$70.96
P/E Ratio
$59.04
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.44
$13.26
52 Week High
$14.05
$39.59

Technical Indicators

Market Signals
Indicator
HOPE
URGN
Relative Strength Index (RSI) 62.14 78.79
Support Level $12.17 $18.58
Resistance Level N/A N/A
Average True Range (ATR) 0.30 1.78
MACD 0.05 0.44
Stochastic Oscillator 68.03 84.75

Price Performance

Historical Comparison
HOPE
URGN

About HOPE Hope Bancorp Inc.

Hope Bancorp Inc is a bank holding company engaged in providing financial services. It offers core business banking products for small and medium-sized businesses and individuals. Services offered by the bank include online banking, mobile banking, mortgage loans, credit cards, investment and wealth management services, and other banking services.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: